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We would like to welcome you as readers, to the
first issue of Allergy, Asthma, and Clinical
Immunology, the Journal of the Canadian Society
of Allergy and Clinical Immunology.
To reach this point has taken a great deal of
patient effort by the Members of the Board of the
Society, by Louise Tremblay and the Executive
Office, and by the Publishers, BC Decker, espe-
cially John Birkby and Carol Hunkeler. 
Most of the work for this issue is the result of
Carol and Keith Payton’s successful collaboration.
Aspecial thanks Keith who stepped back into the
Co-Editor-in-Chief position. 
In April, Keith had suggested that it might be
more efficient if the Editorial Office was located
at a single site and as a result, Wade Watson will
take over as Co-Editor-in-Chief here in Winnipeg,
where mosquitoes and cold ensure dedicated ser-
vice to the Journal 48 weeks of the year.
This issue contains excellent articles on rhino-
sinusitis and the treatment of asthma, as well as the
programme for the fall meeting of the Society, which
hopefully as many as possible of you will attend.
Deserving of comment is that one of the
papers is by John Toogood. As you all are aware,
John has had a long and extremely illustrious
career in allergy and clinical immunology in
Canada. In 1960, Dr. Toogood pioneered the
introduction of inhaled steroid therapy for chronic
asthma. Subsequently, his years of scientific
research on the treatment of asthma have received
national and international scientific recognition.
John has published extensively in the fields of
asthma, allergy, clinical trials methodology, and
medical history. Since his retirement from the
University of Western Ontario in 1993 at the age
of 70, he has published 30 scientific articles and
continues to be a consultant to the pharmaceuti-
cal industry and government on matters related to
drug therapy for asthma. He is an example to us
all, which if followed predicts a great future for
our new Journal. 
Richard Warrington, MB, BS, PhD, FRCPC
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The Canadian Allergy, Asthma and Immunology Foundation (CAAIF) raises monies to fund research and teaching
in allergy, asthma, and immunology. We thank all those who have contributed to CAAIF.   We have also been fortunate
to have enlisted the following partners to help fund fellowships and research awards: Anaphylaxis Canada, Bayer,
Canadian Institutes of Health Research, GlaxoSmithKline, and Merck Frosst. We thank them for their ongoing support. 
We are proud to announce the winners of this year's awards. 
The First Annual Clinical Fellowship was awarded to Greg Appelt; 
The GlaxoSmithKline Fellowship in the field of Allergy and Clinical Immunology was awarded to Dr. Joel Liem
for his project entitled “Is there an association between prematurity/birthweight and asthma”; 
The First Annual Anaphylaxis Award to Encourage Anaphylaxis Research in Canada was awarded to Dr. Kent Hay-
Glass for his project entitled “Peanut allergy vs. clinical tolerance in young adults”;
The Research Institute of Fragrance Management awarded Dr. Karen Binkley a fellowship for her project entitled “Genetics
and stress responses in idiopathic environmental intolerance and other unexplained multisystem disorders”. 
Many thanks to all for your support of the Foundation!
Zave Chad, MD 
Chair, CAAIF